(3) Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R and Jones R (2025) Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study
Membership Special Kassandra Bio Kassandra Tucker, RN, BSN, a nurse injector passionate about Aesthetics, started her career in Neurosurgical ICU and Pre/Post Op in 2016
The FDA grants several forms of non-patent market exclusivity: New Chemical Entity (NCE) Exclusivity provides five years of data exclusivity from the date of approval for a drug containing a previously unapproved active moiety [26]
This is likely a result of our NMA using a smaller set of studies to better reflect clinical practice, including only those which report on doses of semaglutide and liraglutide approved for weight management and excluding those using intensive behavioural therapy
Shah UK, Chaudhary S, Ghimire A, et al